DE2246969C2 - Urokinase-Heparinat und dieses enthaltende Arzneimittel - Google Patents
Urokinase-Heparinat und dieses enthaltende ArzneimittelInfo
- Publication number
- DE2246969C2 DE2246969C2 DE2246969A DE2246969A DE2246969C2 DE 2246969 C2 DE2246969 C2 DE 2246969C2 DE 2246969 A DE2246969 A DE 2246969A DE 2246969 A DE2246969 A DE 2246969A DE 2246969 C2 DE2246969 C2 DE 2246969C2
- Authority
- DE
- Germany
- Prior art keywords
- urokinase
- solution
- heparinate
- activity
- microsiemens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims description 186
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title claims description 186
- 229960005356 urokinase Drugs 0.000 title claims description 182
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 79
- 229920000669 heparin Polymers 0.000 title claims description 79
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000243 solution Substances 0.000 claims description 140
- 230000000694 effects Effects 0.000 claims description 55
- 239000002244 precipitate Substances 0.000 claims description 34
- 230000010412 perfusion Effects 0.000 claims description 25
- 229960002897 heparin Drugs 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 35
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 33
- 235000011130 ammonium sulphate Nutrition 0.000 description 33
- 238000011282 treatment Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 22
- 229920005989 resin Polymers 0.000 description 21
- 239000011347 resin Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 238000005119 centrifugation Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- 239000005995 Aluminium silicate Substances 0.000 description 18
- 235000012211 aluminium silicate Nutrition 0.000 description 18
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 230000001698 pyrogenic effect Effects 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 description 14
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 14
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 206010001497 Agitation Diseases 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- 238000013019 agitation Methods 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000002270 exclusion chromatography Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 210000002196 fr. b Anatomy 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000005377 adsorption chromatography Methods 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010020843 Hyperthermia Diseases 0.000 description 3
- 208000031816 Pathologic Dilatation Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000011082 depyrogenation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 210000000540 fraction c Anatomy 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000036031 hyperthermia Effects 0.000 description 3
- 229910052573 porcelain Inorganic materials 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012461 cellulose resin Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940043200 pentothal Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 210000001698 popliteal fossa Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7134435A FR2153200A1 (en) | 1971-09-24 | 1971-09-24 | Stable,pyrogen-free urokinase prepns - from human urine |
| FR7223867A FR2190412A1 (en) | 1972-06-30 | 1972-06-30 | Stable,pyrogen-free urokinase prepns - from human urine |
| FR7223868A FR2190413A2 (en) | 1972-06-30 | 1972-06-30 | Stable,pyrogen-free urokinase prepns - from human urine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2246969A1 DE2246969A1 (de) | 1973-04-05 |
| DE2246969C2 true DE2246969C2 (de) | 1986-12-11 |
Family
ID=27249660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2246969A Expired DE2246969C2 (de) | 1971-09-24 | 1972-09-25 | Urokinase-Heparinat und dieses enthaltende Arzneimittel |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS5718465B2 (en, 2012) |
| BE (1) | BE789189A (en, 2012) |
| CA (1) | CA986013A (en, 2012) |
| CH (2) | CH604726A5 (en, 2012) |
| DE (1) | DE2246969C2 (en, 2012) |
| DK (1) | DK133130C (en, 2012) |
| ES (3) | ES406980A1 (en, 2012) |
| GB (2) | GB1411421A (en, 2012) |
| IN (1) | IN141112B (en, 2012) |
| NL (1) | NL7212891A (en, 2012) |
| SE (2) | SE405806B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2428248B2 (de) * | 1973-07-24 | 1978-01-12 | Serna Ag, Glarus (Schweiz) | Verfahren zur herstellung von pyrogenfreier urokinase |
| US3957582A (en) * | 1974-11-20 | 1976-05-18 | Abbott Laboratories | Purification of urokinase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3256158A (en) * | 1963-03-22 | 1966-06-14 | Abbott Lab | Purification of urokinase |
| US3355361A (en) * | 1964-10-15 | 1967-11-28 | Sterling Drug Inc | Recovery and purification of urokinase |
| US3477912A (en) * | 1967-07-07 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
| US3477913A (en) * | 1967-10-31 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
-
0
- BE BE789189D patent/BE789189A/xx not_active IP Right Cessation
-
1972
- 1972-09-21 SE SE7212220A patent/SE405806B/sv unknown
- 1972-09-22 NL NL7212891A patent/NL7212891A/xx active Search and Examination
- 1972-09-22 DK DK470672A patent/DK133130C/da not_active IP Right Cessation
- 1972-09-22 JP JP9561172A patent/JPS5718465B2/ja not_active Expired
- 1972-09-22 GB GB4400372A patent/GB1411421A/en not_active Expired
- 1972-09-22 GB GB1550275A patent/GB1411422A/en not_active Expired
- 1972-09-22 CH CH1715974A patent/CH604726A5/xx not_active IP Right Cessation
- 1972-09-22 CA CA152,328A patent/CA986013A/en not_active Expired
- 1972-09-22 CH CH1384072A patent/CH560050A5/xx not_active IP Right Cessation
- 1972-09-23 ES ES406980A patent/ES406980A1/es not_active Expired
- 1972-09-25 DE DE2246969A patent/DE2246969C2/de not_active Expired
-
1973
- 1973-09-17 IN IN2122/CAL/1973A patent/IN141112B/en unknown
-
1975
- 1975-08-14 ES ES440244A patent/ES440244A1/es not_active Expired
- 1975-12-30 SE SE7514792A patent/SE7514792L/xx unknown
-
1977
- 1977-02-16 ES ES455975A patent/ES455975A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4856888A (en, 2012) | 1973-08-09 |
| CH604726A5 (en, 2012) | 1978-09-15 |
| BE789189A (fr) | 1973-03-22 |
| GB1411422A (en) | 1975-10-22 |
| ES406980A1 (es) | 1976-06-16 |
| SE7514792L (sv) | 1975-12-30 |
| CA986013A (en) | 1976-03-23 |
| GB1411421A (en) | 1975-10-22 |
| SE405806B (sv) | 1979-01-08 |
| DK133130B (da) | 1976-03-29 |
| ES440244A1 (es) | 1977-08-01 |
| NL7212891A (en, 2012) | 1973-03-27 |
| CH560050A5 (en, 2012) | 1975-03-27 |
| DK133130C (da) | 1976-09-27 |
| IN141112B (en, 2012) | 1977-01-22 |
| DE2246969A1 (de) | 1973-04-05 |
| ES455975A1 (es) | 1978-03-01 |
| JPS5718465B2 (en, 2012) | 1982-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3150318C2 (de) | "Verfahren zur Herstellung eines Polysaccharidderivats des Fibrinolysins" | |
| DE69011703T2 (de) | Therapeutisches Arzneimittel gegen Thrombose und Verfahren zur Herstellung. | |
| DE3433329A1 (de) | Pharmazeutische zusammensetzung zur behandlung der stadien akuter niereninsuffizienz | |
| DE2944792A1 (de) | Mucopolysaccharidfraktion, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE3026180A1 (de) | Verwendung von rifamycin sv und seinen salzen in form von praeparaten zur intraartikulaeren injektion bei der bekaempfung von rheumatoider arthritis | |
| DE69521388T2 (de) | Verwendung von Glycosaminoglycanen zur Herstellung eines Arzneimittels zur Behandlung des chronischen Nierenversagens | |
| DE3037299A1 (de) | Verfahren zur herstellung von chondroitinsulfat | |
| DE2459915A1 (de) | Verbindungen vom plasminogen-typ und verfahren zu deren herstellung | |
| EP0145005A2 (de) | Lungen-Surfactant, Verfahren zu seiner Herstellung und seine pharmazeutische Verwendung | |
| DE1442134C3 (de) | In vivo antikoagulierend wirkendes und defibrinierendes Enzym | |
| DE3306944C2 (en, 2012) | ||
| DE2246969C2 (de) | Urokinase-Heparinat und dieses enthaltende Arzneimittel | |
| DE3019895C2 (en, 2012) | ||
| EP1303294B1 (de) | Verfahren zur behandlung von instabiler angina pectoris | |
| DE4008033C2 (en, 2012) | ||
| DE2715748A1 (de) | Zubereitungen auf der grundlage von verbindungen vom plasminogen-typ, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2262520C3 (de) | Verfahren zur Herstellung eines lyophilisierten, lagerfähigen Konzentrats aus menschlichem Plasma | |
| DE1617279C3 (de) | Verfahren zur Herstellung eines die Aspergillopeptidase ARL 1 enthaltenden Präparates aus Aspergillus oryzae und sie enthaltendes Arzneimittel | |
| AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
| DE2653534C2 (de) | Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung | |
| DE69810724T2 (de) | Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC) | |
| EP0711170B1 (de) | T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen | |
| DE2349186C2 (de) | Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion | |
| DE2409650C3 (de) | Verwendung wäßriger Lösung von menschlichem Serum-Haptoglobin bei der Bekämpfung von hämolytischen Nierenstörungen | |
| DE69113437T2 (de) | Therapeutische Mittel für diabetisches Gangrän. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |